Nils Kriedemann

Jun 15, 2024 | mdpi.com | Anja Schneider |Axel Hage |Nils Kriedemann |Robert Zweigerdt

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Mar 28, 2024 | nature.com | Kevin Ullmann |Felix Manstein |Lika Drakhlis |Ulrich Martin |Nils Kriedemann |Alexandra Haase

AbstractA promising cell-therapy approach for heart failure aims at differentiating human pluripotent stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease-induced loss of patients’ heart muscle cells in vivo. But many challenges remain for the routine clinical application of hPSC-derived CMs (hPSC-CMs), including good manufacturing practice (GMP)-compliant production strategies.